A novel approach for mitigating the persistent coagulopathic risk and high mortality seen in APL treatment induction is the utilization of the anti-CD33 monoclonal antibody gemtuzumab ozogamicin (GO) in lieu of cytotoxic chemotherapy in high-risk APL [124]. The gene discussed is CD33; the disease is acute promyelocytic leukemia.